The clinical applicability of serum tumour markers in patients with non-small-cell lung cancer (NSCLC) seems limited. The available markers are not able to discriminate between operable and inoperable disease and their sensitivity and specificity are not high enough to justify a screening programme (Minna et al., 1989; Bates, 1991) . Moreover, the number of reports about the value of serum tumour markers for disease monitoring of patients with NSCLC during chemotherapy and follow-up is small. Many patients with NSCLC present with advanced disease, and for at least some of these patients treatment with chemotherapy will be considered. The possible benefit of chemotherapy in these patients is small and limited to only a few (Souquet et al., 1993) . Therefore treatment has to be evaluated carefully in order to prevent continuation of ineffective treatment and related toxicity for non-responding patients. (Pujol et al., 1993 analyser. CEA was measured using a commercial kit (CIS bio international, Gif-Sur-Yvette, France), TPA with another commercial kit (Prolifigen RIA Sangtec Medical, Bromma, Sweden) and SCC with a commercial radioimmunoassay from Abbot Diagnostika (Wiesbaden, Germany).
Cut-off values used in this study were 3.3 ng ml1 for Cyfra 21.1, 170U1' for TPA, 7.4ngml-' for CEA and 2.4ngml-' for SCC. These cut-off values correspond to a 95% specificity for all markers determined in 546 patients with non-malignant lung diseases (Rastel et al., 1993) .
TPA and SCC and CEA, but not between CEA and SCC (Table III ). An example of a scatter diagram of Cyfra 21.1 and TPA is given in Figure 3 .
Correlation between the Cyfra 21.1 radioimmunometric assay and the Cyfra 21.1 enzyme immunoassay A scatter diagram of the assay results of 200 different samples measured by the Cyfra 21.1 radioimmunometric assay and the Cyfra 21.1 enzyme immunoassay is shown in Figure  4 . After logarithmic transformation of the values, the correlation coefficient between the two assays was 0.99.
Disease monitoring with Cyfra 21.1 in patients with squamous cell lung carcinoma Of the 80 patients with a squamous cell carcinoma, 49 (61%) fulfilled the following criteria: (1) treated with chemotherapy;
Statistical methods
The variables Cyfra 21.1, SCC, CEA and TPA were log transformed before calculation of correlation coefficients. Correlation coefficients were assessed by simple linear regression analysis. For testing significance Student's t-test was used. A P-value less than 0.05 was considered significant.
Results

Sensitivity
Patient characteristics are listed in Table I . The four tumour markers were determined in all 212 patients. The median assay value for Cyfra 21.1 was 2.0ng ml' (range 0-1057), for CEA 4.5 ng ml-' (range 0.2-3969), for TPA 122 U 1-' (range 23-29121) and for SCC I.Ongml-' (range 0-141).
At least one elevated marker concentration was found in 146 patients (69%). When a combination of two markers was used, 61% of the patients had an elevated CEA or TPA or an elevated CEA or Cyfra 21.1. Thirty-one per cent of patients had normal values for all four markers.
Higher median CEA values were found in patients with adenocarcinomas than in patients with squamous cell carcinoma or large-cell undifferentiated carcinoma, whereas higher median levels of Cyfra 21.1 and SCC were found in patients with squamous cell carcinoma compared with the other two histological types. The percentages of patients with a marker level above the cut-off level for all patients according to different histological type are listed in Table II . The sensitivity of the four markers by stage IlIa, IIIb and IV is shown in Figure 1 . The sensitivity of the markers in squamous cell carcinoma according to the different stages is shown in Figure 2 .
A significant inter-marker correlation was observed between Cyfra 21.1 and CEA, between TPA and SCC, and between (33) obtained by the clinical evaluation by 1 or 2 months. On three of these four occasions the marker indicated that disease progression had occurred while the clinical diagnosis was still stable disease. The remaining event occurred in a patient in whom normalisation of the marker and clinically stable disease was followed by a partial response. A negative lead time was observed on one occasion in a patient with progressive disease in whom the tumour marker met the criteria for progressive disease only 4 weeks later. In ten cases the clinical response was partial response while Cyfra 21.1 levels had dropped below the cut-off level. In three evaluations the clinical evaluation was of stable disease although tumour regression was observed and a partial response of the marker was observed on one occasion and a complete response of the marker on t,wo occasions.
In one patient the marker indicated progression but the clinical evaluation was stable disease. This patient was subseqently treated with radiotherapy so that the possibility of a positive lead time of the marker could not be assessed. On one occasion the marker level increased when clinical progression was documented but not sufficiently to meet the criteria set for marker progression. A summary of the discordant evaluations is given in Table V . (Moll et al., 1982) . The principal function of most intermediate filaments is most likely to provide mechanical support to the cell and its nucleus (Geiger, 1987) .
In this study we first investigated the value of the newly developed marker Cyfra 21.1 in patients with non-small-cell lung cancer and compared it with three other tumour markers: CEA, SCC and TPA. As can be seen in Table II the overall sensitivity of Cyfra 21.1 was similar to the sensitivity of CEA and TPA but significantly higher than the sensitivity of SCC. This is also true for patients with large-cell lung carcinoma. In patients with adenocarcinomas the sensitivity of CEA was significantly higher than the sensitivity of the three other markers tested, while in patients with squamous cell carcinoma Cyfra 21.1 had the highest sensitivity although not significantly higher than the sensitivity of TPA. Although the overall sensitivity of Cyfra 21.1 in the studied group, including most patients with advanced disease, was 40%, it can be anticipated that this is far too low for screening purposes. An increased sensitivity was found in the higher stages, but considerable overlap is observed between the various stages.
It is interesting to speculate why the sensitivity of Cyfra 21.1 is higher in patients with squamous cell carcinoma than in patients with adenocarcinoma. Since cytokeratins are generally released during cell death, this suggests either that the content of cytokeratin 19 in squamous carcinoma cells is higher than in adenocarcinoma cells or that the cell loss factor is larger in patients with squamous cell carcinoma. Although cytokeratin 19 is widely distributed in epithelial tissues and generally regarded as characteristic of simple epithelia, a relation with the keratinocyte keratins has been suggested (Bartek et al., 1985; Stasiak et al., 1989) . The fact that the sensitivity of TPA is also higher in patients with squamous cell carcinoma than in patients with adenocarcinoma argues against the hypothesis that the increased sensitivity is only related to squamous cell differentiation. A highly significant inter-marker correlation was found, especially between TPA and Cyfra 21.1. This observation may suggest that these two markers are related to the same cells or bear the same relationship with the total tumour load. The value of Cyfra 21.1 for disease monitoring could be evaluated in 23 patients. When the cases with lead time were included a concordance between clinical evaluation according to WHO response criteria and evaluation according to changes in the marker levels of 74% was observed. Most of the discordant evaluations were caused by patients who achieved minor regression or a partial response to chemotherapy while the marker level dropped below the cut-off level. When the cases in which the clinical evaluation was partial response while a normalisation of the marker took place were alone not considered to be discordant, the percentage of discordant evaluations drops to 9%. Progression of the marker with clinical stable diseasae was observed only once. The possible explanation for this occurrence was a positive lead time of the marker in a patient with stable disease who was not evaluable for further response evaluation because of subsequent radiotherapy. In all the other cases a 40% increase in the level of Cyfra 21.1 indicated disease progression.
In conclusion, Cyfra 21.1 seems to be a valuable tumour marker for disease monitoring at least in patients with squamous cell lung cancer, especially since increasing levels of this marker usually indicated disease progression, and such knowledge obtained in an easy way may prevent continuation of ineffective toxic treatment.
